The Israeli burns and wound management company has hired an investment bank that specializes in mergers and acquisitions.
PixCell's HemoScreen performs a complete blood count within 5 minutes enabling physicians to diagnose and treat their patients during a single visit.
The offering by the Israeli company, scheduled for March 23, is planned at a $370 million company value.
CFO Michael McClellan: Nothing really ever came out of NTE so we terminated it.
David Silver was until recently Senior IP Director and Chief Scientist in Teva's Intellectual Property Department.
Teva is returning the rights to commercialize the small molecule gene-related peptide CGRP antagonist HTL0022562 as part of its streamlining plan.
Haifa-based Accellta has developed technology for high speed mass culturing of stem cells.
Cogentix, sold to Canadian company Laborie for $242 million, is the biggest success so far for Accelmed's investment model.
Israeli microbiome company MyBiotics Pharma's MyCrobe technology aims to let good bacteria live longer in the gut.
Merck CEO Dr. Stefan Oschmann is reluctant to comment on Teva, but comparisons are inevitable.
NRS believes that biological developments for improving agriculture can lead to a breakthrough in understanding biological mechanisms in people.
ALYNnovation takes medical innovations developed at the ALYN pediatric rehabilitation hospital out of the hospital so that all children can benefit from them.
Freddy Zinger does not rule out buying Teva Migada in Kiryat Shmona, the company he founded.
Kare Schultz has stabilized the ship but faces enormous opposition to his streamlining plan.
Every change in Teva's business is amplified in its share price.
Teva, Israel's universities and the state should join forces to find and develop new drugs, says Prof. Eyal Winter.
Teva's contribution to Israel's tax revenues has been virtually zero.
As Teva workers await the axe, one tells "Globes" that he fears he will be shortchanged while outgoing CSO Michael Hayden gets $2.5 million by the end of 2018.
Former Teva chairman Meir Heth believes the company's top executives are responsible for the current situation.
Some financial institutions see an opportunity in Teva's low share price and have increased their holdings in the company.
Princeton University's Prof. Dalton Conley tells "Globes" that understanding the interaction between genetics and environment will start a social revolution.
Analyst Steven Tepper tells "Globes" that if Teva wants to stay independent, it needs capital, or it will be exposed to a takeover.
Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.
More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.
Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.
Israeli company Essence develops products that enable people to keep living at home in old age.
The Weizmann Institute researcher's groundbreaking research on Alzheimer's Disease is leading to new treatment for it.